

Org. Commun. 10:4 (2017) 280-287

organic communications

Synthesis and biological activities of some new spiro 1,2,4-triazole derivatives having sulfonamide moiety

Hany M. Dalloul^{1*}, Khaled El-nwairy², Ali Z. Shorafa² and Ahmed Abu Samaha³

¹ Department of Chemistry, Faculty of Applied Science, Alaqsa University of Gaza, P.O.Box 4051, Gaza 76888, Palestine
² Ministry of Education & Higher Education, Beirut Street, Southern Reemal, Gaza 76888, Palestine
³ Department of Biology, Faculty of Applied Science, Alaqsa University of Gaza, P.O.Box 4051, Gaza 76888, Palestine

(Received August 25, 2017; Revised September 09, 2017; Accepted September 11, 2017)

Abstract: A new series of spiro 1,2,4-triazoles **5-9a-j** were prepared by the reaction of appropriate amidrazones **4** with cyclic ketones in catalytic amount of *p*-toluene sulfonic acid. The structures of the titled compounds have been elucidated by the elemental analysis and spectroscopic data (IR, ¹H NMR, ¹³C NMR and MS). The biological activities of the prepared compounds were investigated using well-established methods from the literature.

Keywords: Amidrazone; nitrilimines; spiro 1,2,4-triazole; sulfonamide; cyclic ketone. ©2017 ACG Publications. All rights reserved.

1. Introduction

Amidrazones represent a class of substances with interesting biological properties. The interest in amidrazones and their derivatives stems not only from their biological relevance but also from their applications as precursors and intermediates for the synthesis of many heterocyclic compounds¹⁻³ and as ligands in coordination chemistry. It has been established that they can exhibit antibacterial, antifungal⁴⁻⁶, antitumor⁷ and antituberculosis activities⁸. They were also found as effective herbicides⁹, pesticides¹⁰, and insecticides¹¹. Amidrazones synthesized from different hydrazonoyl halides were reported to react with α -haloesters in the presence of triethylamine as a base under reflux to afford 1,3,5-substituted 4,5-dihydro-1,2,4-triazin-6-ones¹². Several studies, reported the formation and investigation of biological activities of some spiroheterocyclic compounds having triazole, tetrazine thiadiazole, thiadiazines, thiazolidinone and triazine moieties¹³⁻¹⁷. Recently, unknown dispiroheterocycles containing triazole and tetrazine moieties have been disclosed¹⁴⁻¹⁷.

Sulfonamide derivatives are known to exhibit various pharmacological properties such as antiangiogenic, anti-tumor, anti-inflammatory and anti-analgesic, anti-tubercular, anti-glaucoma, anti-HIV, cytotoxic, anti-microbial, anti-malarial agents¹⁸. Considering the previous reports on the biological activities and syntheses of sulfonamides we report here synthesis and antimicrobial activity of new spiroheterocycles having 1,2,4-triazole and piperidone derivatives via cyclization of amidrazones containing sulfonamide moiety with cyclic ketones.

^{*} Corresponding author: E-mail: <u>hmdalloul@yahoo.com</u>

2. Experimental

2.1. Reagents and Instrumentation

Melting points were determined on an A. Krüss Melting Point Meter equipped with a thermometer and are uncorrected. The IR spectra were measured as potassium bromide pellets using a Satellite 3000 Mid infrared spectrophotometer. The ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AM 300 MHz spectrometer at room temperature in DMSO- d_6 solution using tetramethylsilane (TMS) as internal reference. Chemical shifts were recorded as δ values in parts per millions (ppm) downfield from internal TMS. Electron impact (EI) mass spectra were run on a Shimadzu GCMS-QP1000 EX spectrometer at 70 eV. All compounds were analyzed satisfactorily for C, H and N. The amidrazones **4** were prepared according to the literature procedures¹⁹⁻²². Sodium azide, triphenylphosphine and tetrabutylammonium iodide were obtained from Fluka Chemie Company, Switzerland. Sulfathiazole, sulfadiazine, dioxane, tetrahydrofuran (THF) and triethylamine were purchased from Avocado Research Chemicals, England, and used without further purification.

2.2. Synthesis of Spiro 4,5-dihyro-1,2,4-triazole derivatives (5-9a-j).

To a stirred solution of the appropriate amidrazone 4 (10 mmol) and the respective cycloalkanone (20 mmol) in dioxane (50 mL), the catalytic amount of *p*-toluenesulfonic acid (0.1 g) was added. The reaction mixture was refluxed to the completion (monitoring the reaction progress by TLC). The excess of the solvent was evaporated and the residue was triturated with methanol or ethanol. The resulting crude solid product was collected and recrystallized from ethanol. The following compounds were prepared using this method:

3-Acetyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (5a): Yield: 65%; m.p.: 197-199 °C; IR (KBr) v_{max} : cm⁻¹ 3382, 3355 (NH's), 1695 (CH₃-C=O), 1622 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.70 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.71 (d, 1H, thiazole), 6.62 (d, 1H, thiazole), 5.65 (s, 1H, NH triazole ring), 2.45 (*s*, 3H, COCH₃), 2.37-1.60 (m, 8H, cyclopentane); ¹³C NMR (DMSO-*d*₆): δ 192.3 (C=O), 169.1, 142.2, 139.6, 135.4, 129.6, 127.4, 119.1, 116.5 (Ar-C, C=N and thiazole-C), 92.8 (spiro-C), 34.9, 24.9 (cyclopentane-C), 26.5 (CH₃); MS: *m/z* 405 [M⁺]; Anal. Calcd. for C₁₇H₁₉N₅O₃S₂ (405.50): C, 50.35; H, 4.72; N, 17.27; Found: C, 50.57; H, 4.60; N, 17.15.

3-Acetyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (**5b**): Yield: 71%; m.p.: 216-218 °C; IR (KBr) v_{max} : cm⁻¹ 3374, 3350 (NH's), 1693 (CH₃-C=O), 1626 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.74 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.41 (d, 2H, pyrimidine), 6.83 (t, 1H, pyrimidine), 5.63 (s, 1H, NH triazole ring), 2.55 (*s*, 3H, COCH₃), 2.37-1.60 (m, 8H, cyclopentane); ¹³C NMR (DMSO-*d*₆): δ 192.1 (C=O), 168.1, 156.4, 142.2, 139.7, 129.8, 127.3, 119.2, 110.6 (Ar-C, C=N and pyrimidine-C), 92.6 (spiro-C), 34.8, 24.6 (cyclopentane-C), 26.6 (CH₃); MS: *m/z* 400 [M⁺]; Anal. Calcd. for C₁₈H₂₀N₆O₃S (400.46): C, 53.99; H, 5.03; N, 20.99; Found: C, 54.23; H, 4.92; N, 21.10.

3-Acetyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.5]dec-2-ene (5c): Yield: 66%; m.p.: 204-206 °C; IR (KBr) v_{max} : cm⁻¹ 3369, 3357 (NH's), 1695 (CH₃-C=O), 1624 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.76 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.71 (d, 1H, thiazole), 6.65 (d, 1H, thiazole), 5.65 (s, 1H, NH triazole ring), 2.54 (*s*, 3H, COCH₃), 2.07-1.16 (m, 10H, cyclohexane); ¹³C NMR (DMSO-*d*₆): δ 192.4 (C=O), 168.4, 142.2, 139.3, 135.5, 129.7, 127.3, 119.2, 116.2 (Ar-C, C=N and thiazole-C), 92.1 (spiro-C), 35.9, 24.8, 23.2 (cyclohexane-C), 26.5 (CH₃); MS: *m/z* 419 [M⁺]; Anal. Calcd. for C₁₈H₂₁N₅O₃S₂ (419.53): C, 61.53; H, 5.05; N, 16.69; Found: C, 61.70; H, 4.96; N, 16.55.

3-Acetyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.5]dec-2-ene (5d): Yield: 65%; m.p.: 192-194 °C; IR (KBr) v_{max} : cm⁻¹ 3377, 3357 (NH's), 1693 (CH₃-C=O), 1628 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.71 (s, 1H, SO₂NH), 8.27-7.06 (m, 4H, Ar-H), 8.40 (d, 2H, pyrimidine), 6.82 (t, 1H, pyrimidine), 5.61 (s, 1H, NH triazole ring), 2.55 (s, 3H, COCH₃), 1.98-1.16 (m, 10H, cyclohexane); ¹³C NMR (DMSO-d₆): δ 191.9 (C=O), 168.2, 156.5, 142.3, 139.4, 135.5, 129.6, 127.5, 119.3, 110.4 (Ar-C, C=N and pyrimidine-C), 91.8 (spiro-C), 35.8, 24.6, 23.1 (cyclohexane-C), 26.4 (CH₃); MS: *m/z* 414

 $[M^+]$; Anal. Calcd. for $C_{19}H_{22}N_6O_2S$ (414.49): C, 55.06; H, 5.35; N, 20.28; Found: C, 54.78; H, 5.50; N, 20.39.

3-Acetyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.6]undec-2-ene (**5e**): Yield: 67%; m.p.: 178-180 °C; IR (KBr) v_{max} : cm⁻¹ 3375, 3358 (NH's), 1695 (CH₃-C=O), 1625 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.76, (s, 1H, NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.70 (d, 1H, thiazole), 6.64 (d, 1H, thiazole), 5.63 (s, 1H, NH triazole ring), 2.54 (*s*, 3H, COCH₃), 2.35-1.42 (m, 12H, cycloheptane); ¹³C NMR (DMSO-*d*₆): δ 192.4 (C=O), 168.2, 142.3, 139.4, 135.3, 129.7, 127.4, 119.3, 116.5 (Ar-C, C=N and thiazole-C), 91.6 (spiro-C), 39.4, 28.1, 22.3 (cycloheptane-C), 26.5 (CH₃); MS: *m/z* 433[M⁺]; Anal. Calcd. for C₁₉H₂₃N₅O₃S₂ (433.55): C, 52.64; H, 5.35; N, 16.15; Found: C, 52.45; H, 5.24; N, 16.03.

3-Acetyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.6]undec-2-ene (*5f*): Yield: 64%; m.p.: 188-190 °C; IR (KBr) v_{max} : cm⁻¹ 3373, 3365 (NH's), 1695 (CH₃-C=O), 1620 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.69 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.36 (d, 2H, pyrimidine), 6.81 (t, 1H, pyrimidine), 5.62 (s, 1H, NH triazole ring), 2.56 (*s*, 3H, COCH₃), 2.34-1.40 (m, 12H, cycloheptane); ¹³C NMR (DMSO-*d*₆): δ 191.8 (C=O), 168.3, 156.7, 142.5, 139.6, 135.1, 129.3, 127.4, 119.2, 110.4 (Ar-C, C=N and pyrimidine-C), 39.1, 28.3, 22.5 (cycloheptane-C), 91.8 (spiro-C), 26.4 (CH₃); MS: *m/z* 428 [M⁺]; Anal. Calcd. for C₂₀H₂₄N₆O₃S (428.52): C, 56.06; H, 5.65; N, 19.61; Found: C, 55.86; H, 5.53; N, 19.47.

3-Acetyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.7]dodec-2-ene (**5g**): Yield: 70%; m.p.: 166-168 °C; IR (KBr) v_{max} : cm⁻¹ 3373, 3361 (NH), 1696 (CH₃-C=O), 1627 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.71 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.72 (d, 1H, thiazole), 6.61 (d, 1H, thiazole), 5.65 (s, 1H, NH triazole ring), 2.55 (*s*, 3H, COCH₃), 2.42-1.24 (m, 14H, cyclooctane); ¹³C NMR (DMSO-*d*₆): δ 192.3 (C=O), 168.5, 142.3, 139.7, 135.5, 129.4, 127.6, 119.4, 116.5 (Ar-C, C=N and thiazole-C), 90.9 (spiro-C), 41.9, 36.5, 27.2, 21.8 (cyclooctane-C), 26.5 (CH₃); MS: *m/z* 447 [M⁺]; Anal. Calcd. for C₂₀H₂₅N₅O₃S₂ (447.58): C, 53.67; H, 5.63; N, 15.65; Found: C, 53.45; H, 5.75; N, 15.55.

3-Acetyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.7]dodec-2-ene (**5h**): Yield: 65%; m.p.: 169-171 °C; IR (KBr) v_{max} : cm⁻¹ 3366, 3360 (NH's), 1692 (CH₃-C=O), 1626 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.76 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 4H, Ar-H), 8.40 (d, 2H, pyrimidine), 6.81 (t, 1H, pyrimidine), 5.66 (s, 1H, NH triazole ring), 2.55 (*s*, 3H, COCH₃), 2.42-1.24 (m, 14H, cyclooctane); ¹³C NMR (DMSO-*d*₆): δ 192.2 (C=O), 168.1, 156.3, 142.0, 139.4, 135.2, 129.4, 127.2, 119.0, 110.2 (Ar-C, C=N and pyrimidine-C), 91.8 (spiro-C), 41.8, 36.3, 27.1, 21.6 (cyclooctane-C), 26.6 (CH₃); MS: *m/z* 442 [M⁺]; Anal. Calcd. for C₂₁H₂₆N₆O₃S (442.54): C, 57.00; H, 5.92; N, 18.99; Found: C, 56.85; H, 6.05; N, 18.87.

3-Acetyl-8-methyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.5]dec-2-ene (5i): Yield: 71%; m.p.: 186-188 °C; IR (KBr) v_{max} : cm⁻¹ 3374, 3355 (NH's), 1693 (CH₃-C=O), 1622 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.70 (s, 1H, SO₂NH), 8.27-7.06 (m, 4H, Ar-H), 8.71 (d, 1H, thiazole), 6.65 (d, 1H, thiazole), 5.64 (s, 1H, NH triazole ring), 2.54 (s, 3H, COCH₃), 2.07-1.14 (m, 8H, cyclohexane), 0.98 (3H, s, CH₃); ¹³C NMR (DMSO-d₆): δ 189.9 (C=O), 168.2, 142.2, 139.6, 135.4, 129.6, 127.4, 119.2, 116.5 (Ar-C, C=N and thiazole-C), 34.9, 27.8, 22.4 (cyclohexane-C), 90.9 (spiro-C), 31.4 (CH₃ at cyclohexane ring) 26.5 (CH₃); MS: *m/z* 433 [M⁺]; Anal. Calcd. for C₁₉H₂₃N₅O₃S₂ (433.55): C, 52.64; H, 5.35; N, 16.15; Found: C, 52.85; H, 5.20; N, 16.28.

3-Acetyl-8-tert-butyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro-[4.5]dec-2-ene (5j): Yield: 69%; m.p.: 199-201 °C; IR (KBr) v_{max} : cm⁻¹ 3370, 3353, (NH's), 1695 (CH₃-C=O) 1622 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.69 (s, 1H, SO₂NH), 8.27-7.06 (m, 4H, Ar-H), 8.68 (d, 1H, thiazole), 6.63 (d, 1H, thiazole), 5.57 (s, 1H, NH triazole ring), 2.57 (s, 3H, COCH₃), 2.05-1.13 (m, 8H, cyclohexane), 0.92 (9H, s, (CH₃)₃C); ¹³C NMR (DMSO-d₆): δ 189.9 (C=O), 168.2, 142.2, 139.6, 135.4, 129.6, 127.4, 119.1, 116.5 (Ar-C, C=N and thiazole-C), 90.8 (spiro-C), 35.2, 27.9, 22.6 (cyclohexane-C), 46.9, 35.7, 32.4, 24.0 (*tert*-butyl carbons), 26.4 (CH₃); MS: *m/z* 470 [M⁺]; Anal. Calcd. for C₂₃H₃₀N₆O₃S (470.60): C, 58.70; H, 6.43; N, 17.86; Found: C, 58.55; H, 6.31; N, 17.95.

3-Benzoyl-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (6a): Yield: 66%; m.p.: 219-221 °C; IR (KBr) v_{max} : cm⁻¹ 3368, 3345 (NH's), 1675 (Ph-C=O), 1596 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.56 (s, 1H, SO₂NH), 8.27-7.06 (m, 9H, Ar-H), 8.74 (d, 1H, thiazole), 6.60 (d, 1H, thiazole), 5.63 (s, 1H, NH triazole ring), 89.8 (spiro-C), 2.37-1.60 (m, 8H, cyclopentane); ¹³C NMR (DMSO-d₆): δ 185.2 (C=O), 167.9, 145.7, 142.4, 140.9, 139.1, 135.4, 130.4, 129.6, 126.3, 125.3, 119.3, 116.2 (Ar-C, C=N and thiazole-C), 34.6, 24.7 (cyclopentane-C); MS: *m/z* 467 [M⁺]; Anal. Calcd. for C₂₂H₂₁N₅O₃S₂ (467.57): C, 56.51; H, 4.53; N, 14.98; Found: C, 56.25; H, 4.40; N, 15.10.

3-Benzoyl-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (6b): Yield: 67%; m.p.: 236-238 °C; IR (KBr) v_{max} : cm⁻¹ 3371, 3347 (NH's), 1676 (Ph-C=O), 1597 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.58 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 9H, Ar-H), 8.44 (d, 2H, pyrimidine), 6.81 (t, 1H, pyrimidine), 5.58 (s, 1H, NH triazole ring), 2.37-1.60 (m, 8H, cyclopentane); ¹³C NMR (DMSO-*d*₆): δ 185.5 (C=O), 168.1, 156.6, 145.6, 142.4, 140.8, 139.3, 130.3, 129.6, 126.3, 125.3, 119.3, 110.2 (Ar-C, C=N and pyrimidine-C), 89.9 (spiro-C), 34.8, 24.7 (cyclopentane-C); MS: *m/z* 462 [M⁺]; Anal. Calcd. for C₂₃H₂₂N₆O₃S (462.53): C, 59.73; H, 4.79; N, 18.17; Found: C, 59.55; H, 4.95; N, 18.05.

3-(2-Furoyl)-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (7*a*): Yield: 70%; m.p.: 197-199 °C; IR (KBr) v_{max} : cm⁻¹ 3375, 3355 (NH's), 1665 (Ar-C=O), 1616 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.63 (*s*, 1H, SO₂NH), 78.27-7.06 (*m*, 7H, Ar-H), 8.66 (d, 1H, thiazole), 6.58 (d, 1H, thiazole), 5.65 (s, 1H, NH triazole ring), 2.37-1.60 (m, 8H, cyclopentane); ¹³C NMR (DMSO-*d*₆): δ 173.6 (C=O), 168.2, 142.2, 139.6, 135.6, 138.8, 129.8, 129.5, 128.2, 127.4, 125.6,119.3, 116.4 (Ar-C, C=N and thiazole-C), 90.6 (spiro-C), 34.7, 24.6 (cyclopentane-C); MS: *m/z* 457[M⁺]; Anal. Calcd. for C₂₀H₁₉N₅O₄S₂ (457.53): C, 52.50; H, 4.19; N, 15.31; Found: C, 52.67; H, 4.06; N, 15.43.

3-(2-Furoyl)-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.5]dec-2-ene (7c): Yield: 71%; m.p.: 226-228 °C; IR (KBr) v_{max} : cm⁻¹ 3377, 3352 (NH's), 1666 (Ar-C=O), 1615 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-*d*₆): δ 11.64 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 7H, Ar-H), 8.67 (d, 1H, thiazole), 6.56 (d, 1H, thiazole), 5.60 (s, 1H, NH triazole ring), 2.05-1.12 (m, 10H, cyclohexane); ¹³C NMR (DMSO-*d*₆): δ 173.5 (C=O), 168.2, 142.3, 139.7, 135.7, 138.8, 129.8, 129.2, 128.2, 127.3, 125.6, 119.4, 116.5 (Ar-C, C=N and thiazole-C), 90.4 (spiro-C), 36.2, 25.1, 23.2 (cyclohexane-C); MS: *m/z* 471 [M⁺]; Anal. Calcd. for C₂₁H₂₁N₅O₄S₂ (471.56): C, 53.49; H, 4.49; N, 14.85; Found: C, 53.35; H, 4.55; N, 14.73.

3-(2-Thenoyl)-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (**8a**): Yield: 72%; m.p.: 218-220 °C; IR (KBr) v_{max} : cm⁻¹ 3365, 3345 (NH's), 1665 (Ar- C=O), 1612 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.66, (s, 1H, SO₂NH), 8.27-7.06 (*m*, 7H, Ar-H), 8.70 (d, 1H, thiazole), 6.63 (d, 1H, thiazole), 5.63 (s, 1H, NH triazole ring), 2.35-1.58 (m, 8H, cyclopentane); ¹³C NMR (DMSO-d₆): δ 174.6 (C=O), 168.1, 145.4, 142.2, 141.8, 135.6, 134.8, 129.4, 128.0, 127.8, 125.7, 120.8, 116.2 (Ar-C, C=N and thiazole-C), 88.8 (spiro-C), 34.8, 24.9 (cyclopentane-C); MS: *m/z* 473[M⁺]; Anal. Calcd. for C₂₀H₁₉N₅O₃S₂ (473.60): C, 50.72; H, 4.04; N, 14.79; Found: C, 50.90; H, 3.90; N, 14.65.

3-(2-Thenoyl)-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.5]-dec-2-ene (8d): Yield: 73%; m.p.: 198-200 °C; IR (KBr) v_{max} : cm⁻¹ 3365, 3346 (NH's), 1660 (Ar-C=O), 1610 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.59 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 7H, Ar-H), 8.38 (d, 2H, pyrimidine), 6.81 (t, 1H, pyrimidine), 5.61 (s, 1H, NH triazole ring), 2.04-1.13 (m, 10H, cyclohexane); ¹³C NMR (DMSO-d₆): δ 174.8 (C=O), 168.4, 156.8, 145.6, 142.2, 141.9, 135.7, 129.5, 129.3, 128.5, 125.2, 116.2, 110.5 (Ar-C, C=N and pyrimidine-C), 88.9 (spiro-C), 36.1, 25.3, 23.1 (cyclohexane-C); MS: *m/z* 482 [M⁺]; Anal. Calcd. for C₂₂H₂₂N₆O₃S₂ (482.59): C, 54.76; H, 4.60; N, 17.41; Found: C, 53.60; H, 4.05; N, 19.35.

3-(2-Naphthoyl)-1-[4-(thiazol-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]non-2-ene (**9a**): Yield: 61%; m.p.: 212-213 °C; IR (KBr) ν_{max}: cm⁻¹ 3369, 3350 (NH), 1606 (Ar-C=O), 1608 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.66 (s, 1H, SO₂NH), 8.27-7.06 (m, 11H, Ar-H), 8.76 (d, 1H, thiazole), 6.66 (d, 1H, thiazole), 5.53 (s, 1H, NH triazole ring), 2.37-1.60 (m, 8H, cyclopentane); ¹³C NMR (DMSO-d₆): δ 185.4 (C=O), 168.0, 145.6, 142.7, 141.6, 135.6, 135.7, 132.3, 133.0, 132.7, 130.0, 128.9, 128.5, 127.9, 127.7, 126.6, 125.6, 120.9, 116.2 (Ar-C, C=N and thiazole-C), 89.8 (spiro-C), 34.9, 24.9 (cyclopentaneC); MS: m/z 517 [M⁺]; Anal. Calcd. for C₂₆H₂₃N₅O₃S₂ (517.63): C, 60.33; H, 4.48; N, 13.53; Found: C, 60.15; H, 4.60; N, 13.65.

3-(2-Naphthoyl)-1-[4-(pyrimidin-2-yl-sulfonyl)phenyl]-1,2,4-triazaspiro[4.4]-non-2-ene (**9b**): Yield: 62%; m.p.: 165-167 °C; IR (KBr) v_{max} : cm⁻¹ 3367, 3355 (NH's), 1655 (Ar-C=O), 1605 (C=N), 1346, 1175 (SO₂); ¹H NMR (DMSO-d₆): δ 11.67 (*s*, 1H, SO₂NH), 8.27-7.06 (*m*, 11H, Ar-H), 8.46 (d, 2H, pyrimidine), 6.85 (t, 1H, pyrimidine), 5.55 (s, 1H, NH triazole ring), 2.34-1.51 (m, 8H, cyclopentane); ¹³C NMR (DMSO-d₆): δ 185.6 (C=O), 168.2, 156.6, 145.6, 142.7, 141.6, 135.6, 132.3, 133.2, 132.7, 130.1, 128.9, 128.5, 127.9, 127.6, 126.8, 125.7, 120.9, 110.4 (Ar-C, C=N and pyrimidine-C), 89.7 (spiro-C), 34.8, 24.7 (cyclopentane-C); MS: *m/z* 512 [M⁺]; Anal. Calcd. for C₂₇H₂₄N₆O₃S (512.59): C, 63.27; H, 4.72; N, 16.40; Found: C, 63.40; H, 4.62; N, 16.28.

3. Results and Discussion

The precursors of amidrazones hydrazonoyl halides 1 employed, in this study, were prepared according to the reported literature procedures¹⁹⁻²². Treatment of the hydrazonoyl halides 1 with sodium azide in the presence of tetrabutylammonium iodide at room temperature gave azidohydrazones 2 (Figure 1). The obtained hydrazonoyl azides 2 were reacted with triphenylphosphine to afford phosphonimines 3 (Figure 1). It was found that the hydrolysis of compounds 3 with aqueous hydrochloric acid gave triphenylphosphine oxide and amidrazones 4 (Figure 1). A plausible mechanism for this acid hydrolysis could be an initial protonation of nitrogen followed by an attack from oxygen on the phosphorous atom¹⁹.

The condensation of amidrazones **4** with cyclic ketones in refluxing dioxane in the presence of catalytic amount of *p*-toluenesulfonic acid (PTSA) produced spiro 4,5-dihydro-1H-1,2,4-triazole derivatives containing sulfonamide moiety **5-9a-j** (Figure 1) in good yields. The reaction progress was monitored by TLC to follow the completion of the synthesis.

The structures of the newly synthesized amidrazones **4** were elucidated on the basis of their spectroscopic data and elemental analyses. Electron impact (EI) mass spectra of the compounds **4a-j** displayed the correct molecular ions (M^+) in accordance with the suggested structures. The IR spectra exhibited typical stretching absorption bands of C=O of conjugate ketone, anilide and ester groups at about 1725-1650 cm⁻¹, NHs were observed in the region of 3470-3220 cm⁻¹ and 1150, 1060 cm⁻¹ was attributed to SO₂ of sulfonamide group. The ¹H NMR spectra of these amidrazones in DMSO-*d*₆ showed three characteristic signals, i.e. singlet at 12.6-12.4 ppm (SO₂NH), singlet of the NNH group in the region of 6.3-6.0 ppm and singlet of NH₂ near 4.9-5.0 ppm. In addition, the characteristic signal of the CONH group in compounds containing anilide group was observed at about 10.8-9.8 ppm and the expected proton signals of the aromatic rings were in the range of 8.4-6.9 ppm. The ¹³C NMR spectra exhibited characteristic signals for the Ar-C=O carbon at about 192-159 ppm and for the C=N moiety at about 143-141 ppm.

The structural assignment of the prepared spiro 1,2,4-triazoles **5-9a-j** was based on elemental analysis, spectral data and literature values²⁰⁻²². Physical properties, molecular ion peaks and microanalysis are presented in experimental section. The IR spectra of these compounds revealed the presence of NH band of dihydrotriazole ring resonating near 3370-3350 cm⁻¹. In addition to the bands of characteristic functional groups, the ¹H NMR spectra of products **5-9a-j** in DMSO-*d*₆ display a characteristic singlet in the region of 5.6-5.5 ppm due to NH proton of dihydrotriazole ring. Also, the spectra exhibited a characteristic singlet at 12.7-12.6 ppm due to SO₂NH proton. The ¹³C NMR spectra displayed characteristic signals of the suggested structures. The signal at 90-95 ppm, which is attributed to C-5 (spiro carbon) of dihydrotriazole ring was of special significance, which is similar to the reported values of spiro carbons flanked by two nitrogens in five-membered heterocycles^{23,25}. The spectral data of the obtained compounds **5-9a-j** are summarized in the experimental section.




Figure 1. Synthetic pathway for the preparation of compounds 4 and 5-9a-j.

| Diameter of the inhibition zone in mm [*] | | | | | | | |
|--|------------------------|---------|-----------|----------------|-------------|---------------------|----------|
| Cpd. No. | Antibacterial activity | | | | | Antifungal activity | |
| | Euterococci | E. coli | S. aureus | Klebsiella spp | Proteus spp | C. albicans | A. niger |
| 5a | 16 | 17 | 17 | 13 | 16 | 15 | 14 |
| 5b | 13 | 18 | 15 | 11 | 10 | 17 | 18 |
| 5c | 19 | 15 | 11 | 14 | 16 | 18 | 16 |
| 5d | 18 | 16 | 17 | 18 | 19 | 16 | 12 |
| 6b | 16 | 19 | 16 | 19 | 11 | 19 | 11 |
| 7a | 13 | 12 | 14 | 16 | 17 | 16 | 19 |
| 7b | 19 | 15 | 11 | 14 | 16 | 18 | 16 |
| 8 a | 18 | 16 | 17 | 18 | 19 | 16 | 12 |
| 8b | 16 | 19 | 16 | 19 | 11 | 19 | 11 |
| 9a | 13 | 12 | 14 | 16 | 17 | 16 | 19 |
| Tet. ^a | 21 | 20 | 19 | 21 | 22 | _ | _ |
| Flu. ^b | _ | _ | _ | _ | _ | 21 | 23 |
| DMF | _ | _ | - | _ | _ | - | _ |

Table 1. Antimicrobial screening results of the tested compounds

*Calculated as average of three values. ^aTetracycline, ^bFluconazole

A standard nutrient agar disc diffusion method^{26,27} was followed to determine the activity of the synthesized compounds against the sensitive organisms *Euterococci*, *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella spp* and *Proteus spp*, as bacterial strains and two species of fungi, namely *Aspergillus niger* and *Candida albicans*. The compounds were tested at a concentration of 1 mg mL⁻¹ in *N*,*N*-dimethyl formamide (DMF) solution, measuring the average diameter of the inhibition zone in mm. The results showed that all the tested compounds exhibited a marked degree of activity against bacteria and fungi compared with well-known antibacterial and antifungal substances such as tetracycline and fluconazole. According to NCCLS²⁷, inhibition zones for tetracycline and fluconazole < 14 mm is considered resistant, between 15 and 18 mm is considered weakly sensitive and > 19 mm is considered sensitive. Also, the results showed that the degree of inhibition varied with the tested compounds (Table 1). The thiazolyl and pyrimidinyl moieties generally led to a dramatic improvements in activity against both bacteria and fungi. The present study can lead medicinal chemists to design and synthesize similar compounds with enhanced biological potency in future.

4. Conclusion

New series of novel functionalized spiro1,2,4-triazols **5-9a-j** bearing sulfonamide moiety were synthesized upon treatment of amidrazones **4a-j** with cyclic ketones in refluxing dioxane, which were examined for their antimicrobial activities, and they were found to possess various antimicrobial activities towards all the microorganisms tested. Shortly, the biological activity is strongly dependent on the nature and size of the substituents on triazole ring.

Acknowledgements

The authors are great thankful to the Qatar Charity for the financial support of this research through Ibhath grant (GCC-07-06).

ORCID 💿

Hany M. Dalloul: <u>0000-0002-4947-3648</u> Khaled El-nwairy: <u>0000-0001-7824-9680</u> Ali Z. Shorafa: <u>0000-0001-9906-5389</u> Ahmed Abu Samaha: <u>0000-0001-7705-6086</u>

References

- [1] Kuhn, D. G.; Furch, J. A.; Hunt, D. A.; Asselin, M.; Baffic, S. P.; Diehl, R. E.; Miller, T. P.; Palmer, Y. L.; Treacy, M. F.; Trotto, S. H. Cycloalkyl-substituted amidrazones: A novel class of insect control agents. ACS. Symp. Ser. 1998, 686, 185-193.
- [2] Neilson, D. G.; Roger, R.; Heatlie, J. W. M.; Newlands, L. R. Chemistry of amidrazones *Chem. Rev.* **1970**, 70, 151-170.
- [3] Aly, A. A.; Nour-El-Din, A. M. Functionality of amidines and amidrazones Arkivoc 2008, (i), 153-194.
- [4] Mamolo, M. G.; Vio, L.; Banfi, E.; Predominato, M.; Fabris, C.; Asaro, F. Synthesis and antimyco-bacterial activity of some 2-pyridinecarboxyamidrazone derivatives. *IL Farmaco* **1992**, *47*, 1055-1066.
- [5] Mamolo, M. G.; Vio, L.; Banfi, E.; Predominato, M.; Fabris, C.; Asaro, F. Synthesis and antimyco-bacterial activity of some 4-pyridinecarboxyamidrazone derivatives. *IL Farmaco* **1993**, *48*, 529-538.
- [6] Ranft, D.; Seyfarth, T.; Schaper, K. J.; Lehwark-Yvetot, G.; Bruhn, C.; Buge, A. New N¹-Hetaryl-methylenesubstituted amidrazones with potential antimycobacterial activity. *Arch. Pharm. Pharm. Med. Chem.* 1992, 332, 427-430.
- [7] Modzelewska-Banachiewic, B.; Matysiak, J.; Niewiadomy, A. Synthesis and mycological activity of the compounds obtained in the reaction of N³-substituted amidrazones with sulphinyl-bis-2,4-dihydroxy-benzenethioyl. *Eur. J. Med. Chem.* **2001**, *36*, 75-80.
- [8] Abdel-Jalil, R.; J.; Al Momani, E.; Hamad, M.; Voelter, W.; Mubarak, M. S.; Smith, B. H.; Peters, D. G. Synthesis, antitumor activity and electrochemical behavior of some piperazinyl amidrazones. *Monatsh. Chem.* 2010, 141, 251-258.
- [9] Dean, G. S.; Rhodes, S. G.; Coad, M.; Whelan, A. O.; Wheeler, P.; Villareal-Ramos, B.; Mead, E.; Johnson, L.; Clifford, D. J.; Hewinson, R. G.; Vordermeier, H. M. Isoniazid treatment of *Mycobacterium bovis* in cattle as a model for human tuberculosis. *Tuberculosis* 2008, *88*, 586-594.

- [10] Hackmann, J. T. US Patent 2 758 050, 1956; Haldeman, R. G.; Morin, L. T.; Matsuda, K. US Patent 3 073013, 1963.
- [11] Neilson, D. G.; Roger, J. W.; Heatlie, L. R. Chemistry of amidrazones Chem. Rev. 1970, 70, 151-170.
- [12] Dalloul, H. M.; Boyle, P. H. Synthesis of nitrogen-containing heterocycles from the reaction of amidrazones with α-haloesters. *Turkish J. Chem.* 2007, 31, 141-147.
- [13] Borad, M.A.; Bhoia, N.; Prajapatia, N. P.; Patela, H. D. Review of synthesis of spiro heterocyclic compounds from Isatin. Synth. Commun. 2013, 44(7), 897-922.
- [14] Shawali, A. S.; Abdelhamid, A. O. Synthesis of Spiro-heterocycles via 1,3-dipolar cycloadditions of nitrilimines to exoheterocyclic enones. site-, regio- and stereo-selectivities overview. *Curr.Org. Chem.* 2012, 16, 2673-2689.
- [15] Dalloul, H. M.; Synthesis of nitrogen-containing dispiroheterocyles (I) using nitrilimines. *Arkivoc*, **2008** (*xiv*) 234-241.
- [16] Dalloul, H. M.; Abu samaha, A.; Synthesis of nitrogen-containing dispiroheterocyles (II) using nitril-imines. J. Serb. Chem. Soc., 2010, 75, 1473-1479.
- [17] Dalloul, H. M. Synthesis of new spiro-heterocycles containing dihydrotetrazine moiety South. Braz. J. Chem. Soc. 2014, 22, 17-26.
- [18] Mok, B. L. PhD, The Synthesis of Functionalized Sulfonamides *Chemistry Department, University College London, UK*, **2008**.
- [19] Shawali, A. S.; Hassaneen, H. M.; Fahmy, A. A.; Abunada, N. M.; Mousa, H. A. Synthesis and reactions of triphenylphosphoniminoglyoxalic acid anilide arylhydrazones. *Phosphor. Sulfur Sil.* 1990 53, 259-265.
- [20] Ashok, D.; Ganesh, A.; Lakshmi, V.B.; Ravi, S.; Ramesh, B. Microwave assisted synthesis and antimicrobial activity of novel 1-[1/2-(1-Benzyl-1H-[1,2,3]triazol-4-ylmethoxy)-naphthalen-2/1-yl]-3-(1-phenyl-3-aryl-1Hpyrazol-4-yl)-propenones. Org. Commun. 2014, 8, 24-35.
- [21] Sreedhar, B.; Reddy, T.V., Raju, C.N., Reddy, G.V.S. Design, synthesis, characterization and bioassay of novel carboxamide derivatives of Celecoxib. *Org. Commun.* **2016**, *9*, 54-64.
- [22] Drutkowski, G.; Donner, C.; Schulze, I.; Frohberg, P. Novel method for the synthesis of 1,2,4-triazoles and 1,2,4-triazol-3-ones. *Tetrahedron*, 2002, 58, 5317-5326.
- [23] Ferwanah, A.S.; Awadallah, A.M.; El-Sawi, E.A. Dalloul, H.M. Synthesis of dihydro- and tetra-hydro-1,2,4,5tetrazines from the reaction of nitrilimines with 1-Substituted-1-methylhydrazine. *Synth. Commun.* 2003, 33, 1245-1253.
- [24] Dalloul, H. M.; Boyle, P. H. Heterocyclic synthesis using nitrilimines: Part 3. Synthesis of substituted 1,2,4,5-tetrazines and 1,2,4,5-tetraza-2-pentenes. *Heterocycl. Commun.* **2003**, *9*, 507-514.
- [25] Dalloul, H. M.; Heterocyclic synthesis using nitrilimines: Part 4. Synthesis of 3-substituted 1-aryl-1,2,4-triazaspiroalk-2-nes. *Chem. Heterocycl. Comp.* **2004**, *40*, 1402-1407.
- [26] Manika, M.; Chanotiya, C.S.; Darokar, M.; Singh, S.; Bagchi, G.D. Compositional characters and antimicrobial potential of *Artemisia stricta* Edgew. f. *stricta* Pamp. essential oil. *Rec. Nat. Prod.* 2016, 10, 40-46
- [27] Clinical and Laboratory Standards Institute, "Methods for dilution antimicrobial susceptibility tests for bacteria grow aerobically", Approved Standard M7-A4, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2005.

A C G publications © 2017 ACG Publications